AS OF 8/6/2021*
prescribed,
number one in new prescriptions, and more neurologists selected as
brand of choice
dosing
Colette S
Actual Nurtec ODT Patient
prescribed,
number one in new prescriptions, and more neurologists selected as
brand of choice
One medication in a
75 mg dose
puts the
power to treat or
prevent in your
patient's hands1
TREATING MIGRAINE ATTACKS
Once daily PRN. Take one 75 mg ODT, as needed, for acute treatment of migraine.1
Patients with a history of 9 to 14 monthly moderate or severe migraine attacks treated with Nurtec 75 mg as needed up to once per day (median usage 8 tablets/month).2
PREVENTING THE NEXT ONE
Take one 75 mg ODT every other day for preventive treatment of episodic migraine.1
90% of patients in the clinical study adhered to the every other day dosing regimen.3
A non-CGRP acute treatment can be used on days when Nurtec ODT is taken, if needed.3
Nurtec ODT is supplied in a carton containing an 8-pack1
one quick-dissolving dose. anytime. anywhere.1
CGRP: calcitonin gene-related peptide
No titration needed1
Can be taken up to
once daily as needed.
No water necessary.1,*
Can be co‑administered
with oral contraceptives
and antidepressants.1,5,6
Shown to both treat and
prevent attacks,
including in patients
already on a
preventive treatment1
Not contraindicated
in patients with stable
cardiovascular disease
or risk factors.1,7
*Up to 18 doses of Nurtec ODT can be taken per month.1
Convenience of
one rapidly
disintegrating dose1,4
How to Take
ready
Instruct patients to only
remove Nurtec ODT
from the blister pack
immediately before use1
No titration needed1
set
Patients can place
Nurtec ODT on or under
their tongue and it
dissolves within
seconds—no water
needed1,8
go
Patient can carry on after taking a single tablet of 75 mg for either acute or preventive treatment1
Nurtec ODT has
a Tmax of 1.5 hours1
Study designs
For the acute indication, Nurtec was evaluated in a multi‑center, double‑blind, randomized, placebo‑controlled study of 1351 patients (Nurtec ODT 75 mg, n=669; placebo, n=682), with co‑primary endpoints at 2 h for Nurtec ODT vs placebo: pain freedom (21% vs 11%, P<.001) and freedom from most bothersome symptoms (MBS; predefined as photophobia, phonophobia, or nausea; 35% vs 27%; P=.001).1
For the preventive indication, rimegepant 75 mg was evaluated in a multi‑center, double‑blind, randomized, placebo‑controlled study of 695 patients (rimegepant 75 mg, n=348; placebo, n=347) with the primary endpoint being change from baseline in the mean number of monthly migraine days during weeks 9‑12 (-4.3 vs -3.5, P=.01).1
A long-term open label safety study with 1800 patients evaluated rimegepant 75 mg dosed as needed for 52 weeks (N=1514) and dosed every other day plus as needed for 12 weeks (N=286).1,9
References: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 2. Croop R, Berman G, Kudrow D, et al. Long-term safety of rimegepant 75 mg for the acute treatment of migraine (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 3. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2020;397(10268): 51-60. doi:10.1016/S0140-6736(20)32544-7. 4. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. 5. Hutchinson S, Schim J, Lipton RB, et al. Rimegepant is safe and tolerable for the acute treatment of migraine in patients using preventive migraine medications: Results from a long-term open-label safety study (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 6. Baskin SM, Buse DC, Jensen CM, et al. Rimegepant 75 mg is safe and well tolerated for the acute treatment of migraine in adults using selective serotonin reuptake inhibitors and other antidepressants: Results from a long-term open-label safety study (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020. 7. Data on File. RIM130. Biohaven Pharmaceuticals Inc. 8. Abay FB, Ugurlu T. Orally Disintegrating Tablets: A Short Review. J Pharm Drug Devel. 2015;3(3):303-311. doi: 10.15744/2348-9782.3.303. 9. McGinley JS, L'Italien GJ, Thiry AC, et al. Rimegepant 75 mg results in reductions in monthly migraine days: Secondary analysis of a multicenter, open label, long‑term safety study of rimegepant for the acute treatment of migraine. Virtual Poster presented at: American Academy of Neurology 2020 Annual Meeting; 2020.
